Global Blood Therapeutics Inc  

(Public, NASDAQ:GBT)   Watch this stock  
Find more results for John W. Starr, Jr
-0.97 (-4.96%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.35 - 19.32
52 week 16.99 - 57.00
Open 19.32
Vol / Avg. 232,335.00/316,645.00
Mkt cap 537.82M
P/E     -
Div/yield     -
EPS -1.93
Shares 30.46M
Beta     -
Inst. own 91%
Jan 13, 2016
Global Blood Therapeutics Inc at JPMorgan Healthcare Conference (Q&A)
Jan 13, 2016
Global Blood Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
Dec 8, 2015
Global Blood Therapeutics Inc at Oppenheimer Healthcare Conference
Dec 7, 2015
Global Blood Therapeutics Inc Investor Briefing at American Society of Hematology Annual Meeting - Webcast
Nov 12, 2015
Q3 2015 Global Blood Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -57.01% -67.20%
Return on average equity -143.16% -
Employees 47 -
CDP Score - -


400 E Jamie Ct Ste 101
United States - Map
+1-650-7417700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Global Blood Therapeutics, Inc. is a biopharmaceutical company that engages in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate, GBT440, oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized, placebo-controlled, double-blind, single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders, such as acute respiratory distress syndrome, in which increased oxygen delivery is needed. The Company, through its GBT440 or analog, also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE), which is in pre-clinical trials. In addition, the Company develops TBD, an oral kallikrein inhibitor, which are in Phase 1/2 clinical trials.

Officers and directors

Ted W. Love M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Hing Sham Senior Vice President - Chemistry
Age: 63
Bio & Compensation  - Reuters
John Schembri Vice President of Finance and Administration
Age: 53
Bio & Compensation  - Reuters
Peter Radovich Vice President - Program Leadership and Business Strategy
Age: 37
Bio & Compensation  - Reuters
Jung E. Choi Chief Business and Strategy Officer
Age: 46
Bio & Compensation  - Reuters
Eleanor L. Ramos M.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Charles J. Homcy M.D. Director
Age: 67
Bio & Compensation  - Reuters
Scott W Morrison Director
Bio & Compensation  - Reuters
Philip A. Pizzo M.D. Director
Age: 70
Bio & Compensation  - Reuters
Kevin P. Starr Director
Age: 52
Bio & Compensation  - Reuters